Semaglutide Reduces Risk of Osteoporosis and Gout in Obese Type 2 Diabetes Patients: Study
Researchers have found in a new cohort study that semaglutide offers significant protection against osteoporosis and gout in individuals with obesity and type 2 diabetes, outperforming traditional glucose-lowering treatments and contributing to improved metabolic health. This study was published in Endocrine Abstracts by Jo-ching Chen and colleagues.
Although increasingly popular for weight loss, the bone safety profile of semaglutide remained unclear particularly in individuals with different metabolic conditions. This five-year cohort study offers solid evidence that semaglutide can provide additional skeletal benefits, most notably in patients with both obesity and T2D.
The two patient groups were followed over a five-year period.
• Overweight adults with T2D who receive either semaglutide or standard glucose-lowering therapy (sitagliptin, empagliflozin, glipizide)
• Overweight adults without T2D who receive either semaglutide or usual anti-obesity drugs (Contrave, phentermine, Qsymia)
The objective was to evaluate the risk of skeletal outcomes such as osteoporosis, osteoarthritis (hip and knee), gout, and other bone density disorders. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated with Cox proportional hazards models. The results were adjusted for the potential confounders, and Bonferroni correction was performed to adjust for multiple comparisons among nine skeletal outcomes. E-values were employed to determine the likelihood of unmeasured confounding.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.